Patents Assigned to KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
-
Publication number: 20240124842Abstract: Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-? pathway inhibitor.Type: ApplicationFiled: December 22, 2023Publication date: April 18, 2024Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Yoshihiro SOWA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20240084258Abstract: The present invention aims to provide a brown adipocyte and a generation method thereof, a transplantation material containing a brown adipocyte, a prophylactic agent or therapeutic agent containing a brown adipocyte for various diseases and conditions, and use thereof. Provided is a method for generating a brown adipocyte, including converting a differentiated somatic cell of a mammal to a brown adipocyte by culturing the somatic cell in a medium in the presence of at least one kind of a compound selected from the group consisting of (1) a TGF?/SMAD pathway inhibitor, (2) a casein kinase 1 inhibitor, (3) a cAMP inducer and (4) a MEK/ERK pathway inhibitor.Type: ApplicationFiled: November 22, 2023Publication date: March 14, 2024Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao Kishida, Toshiro Yamamoto, Osam Mazda
-
Patent number: 11918630Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (?4?1?1), laminin 511 (?5?1?1), laminin 521 (?5?2?1), or fragments of these.Type: GrantFiled: October 30, 2015Date of Patent: March 5, 2024Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Publication number: 20240041497Abstract: To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.Type: ApplicationFiled: November 29, 2021Publication date: February 8, 2024Applicants: NITTO SEIKO CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Masakazu Ishihara, Yoshimitsu Ueno, Tomoaki Murata, Yukito Otsuki, Yusuke Kobayashi, Yoshinobu Oka, Wook-Cheol Kim, Tetsuo Aida, Sadami Tsutsumi
-
Patent number: 11851681Abstract: Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-? pathway inhibitor.Type: GrantFiled: October 20, 2016Date of Patent: December 26, 2023Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta Yamamoto, Tsunao Kishida, Yoshihiro Sowa, Toshiro Yamamoto, Osam Mazda
-
Publication number: 20230389540Abstract: The present invention relates to a method for freezing a cell structure including freezing a cell structure including fragmented extracellular matrix components, cells and fibrin and having a three-dimensional tissue structure.Type: ApplicationFiled: October 15, 2021Publication date: December 7, 2023Applicants: OSAKA UNIVERSITY, TOPPAN INC., Kyoto Prefectural Public University CorporationInventors: Michiya MATSUSAKI, Fiona LOUIS, Shiro KITANO, Yoshihiro SOWA
-
Patent number: 11834679Abstract: The present invention chiefly aims to provide a process for directly inducing cardiomyocytes from somatic cells without performing artificial gene transfer, a cardiomyocyte obtained thereby, and a composition comprising a combination of chemical compounds capable of using for the said process. The present invention can include a process for producing a cardiomyocyte by inducing differentiation directly from a somatic cell, the process comprising a step of culturing the somatic cell in the presence of a MEK inhibitor and a cAMP inducer, and a cardiomyocyte obtained thereby, and then a composition for producing a cardiomyocyte by inducing differentiation directly from a somatic cell, the composition comprising a MEK inhibitor and a cAMP inducer. The cardiomyocytes obtained according to the present invention are useful in regenerative medicine and the like.Type: GrantFiled: January 24, 2019Date of Patent: December 5, 2023Assignees: Kataoka Corporation, Kyoto Prefectural Public University CorporationInventors: Ping Dai, Yukimasa Takeda, Yoshinori Harada, Junichi Matsumoto, Ayumi Kusaka
-
A STORAGE METHOD OF HUMAN CORNEAL ENDOTHELIAL CELLS AND/OR HUMAN CORNEAL ENDOTHELIAL PRECURSOR CELLS
Publication number: 20230380417Abstract: Human corneal endothelial cells and/or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and/or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.Type: ApplicationFiled: October 19, 2021Publication date: November 30, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Munetoyo TODA, Chie SOTOZONO, Morio UENO -
Patent number: 11826363Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.Type: GrantFiled: October 12, 2018Date of Patent: November 28, 2023Assignees: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Koichi Takayama, Tadaaki Yamada, Tomoko Yasuhiro, Kohei Tanaka
-
Patent number: 11826244Abstract: Provided is an intraocular lens affixing device which makes it possible to affix an intraocular lens of any kind with respect to the inside of an eye with a ruptured or deleted lens capsule. The intraocular lens affixing device 1 is provided with a device support portion (A) and an intraocular lens housing portion (B) connected to the device support portion (A). The device support portion (A) includes a frame 2 having a shape matching a ciliary sulcus 36. Also provided is an affixing kit for inserting an intraocular lens, the kit being provided with a) an intraocular lens affixing device; and b) an injector for injecting the affixing device.Type: GrantFiled: February 13, 2018Date of Patent: November 28, 2023Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventor: Kentaro Kojima
-
Patent number: 11781108Abstract: The present invention provides a method with which it is possible to directly induce nervous system cells efficiently and in a short amount of time. Because the method is easy to scale up and is not affected by the characteristics or background of the somatic cells used as material, the method enables the stable supply of nervous system cells. The nervous system cells obtained by the method are useful in various fields of research and healthcare.Type: GrantFiled: January 18, 2016Date of Patent: October 10, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, KATAOKA CORPORATIONInventors: Ping Dai, Tetsuro Takamatsu
-
Publication number: 20230310402Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: ApplicationFiled: June 7, 2023Publication date: October 5, 2023Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Patent number: 11771735Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.Type: GrantFiled: November 19, 2021Date of Patent: October 3, 2023Assignees: KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITYInventors: Takaomi Kessoku, Atsushi Nakajima, Yoshio Sumida, Yuichiro Eguchi, Susumu Saito, Yusuke Sauchi
-
Publication number: 20230295568Abstract: An object of the present invention is to provide a therapeutic strategy in the solid tumor area and a means useful therefor to further advance the clinical application of CAR therapy. There is prepared a gene-modified lymphocyte which expresses a chimeric antigen receptor having an EphrinB2 extracellular domain at the antigen recognition site.Type: ApplicationFiled: February 13, 2023Publication date: September 21, 2023Applicants: Shinshu University, Kyoto Prefectural Public University CorporationInventors: Hajime Hosoi, Tomoko Iehara, Shigeki Yagyu, Yozo Nakazawa
-
Patent number: 11730722Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: GrantFiled: July 30, 2013Date of Patent: August 22, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Patent number: 11733130Abstract: A tissue dividing jig includes a tissue dividing base; and a cutting blade set provided with a cutting blade member and a guide portion, the tissue dividing base and the cutting blade set have a positioning mechanism that fixes their positions mutually, the cutting blade member is provided with a cutting blade extending in a longitudinal direction of the tissue placement portion, the guide portion guides the cutting blade member to move the cutting blade member to a fixed position on the tissue dividing base, and the cutting blade is disposed such that when the cutting blade set is disposed at a predetermined position on the tissue dividing base by the positioning mechanism and the cutting blade member is moved using the guide portion, the cutting blade divides the needle biopsy tissue on the tissue placement portion in the longitudinal direction.Type: GrantFiled: October 5, 2017Date of Patent: August 22, 2023Assignees: Umihira Co., Ltd., Kyoto Prefectural Public University CorporationInventors: Kazuo Umihira, Keizou Ogino, Osamu Ukimura, Kazumi Kamoi
-
Publication number: 20230257700Abstract: To provide a cell trait assay technique for identifying cultured human corneal endothelium cells of which early clinical effect manifestation and a long-term stable clinical effect are confirmed, in clinical trials. Provided is a method of manufacturing a functional human corneal endothelial cell capable of eliciting a human corneal function when infused into an anterior chamber of a human eye, the method comprising the step of proliferating and/or differentiating or maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress, such as proliferation stress.Type: ApplicationFiled: February 26, 2021Publication date: August 17, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Junji HAMURO, Chie SOTOZONO, Morio UENO, Munetoyo TODA
-
Publication number: 20230241197Abstract: The present invention provides a protein molecule effective for an anti-Pseudomonas aeruginosa vaccine. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.Type: ApplicationFiled: May 13, 2021Publication date: August 3, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventor: Teiji SAWA
-
Publication number: 20230221332Abstract: A method for diagnosing the risk of glaucoma development, which can diagnose the risk of glaucoma development at the pre-disease stage, and to provide a new method to diagnose disease progression in the end-stage glaucoma. The method can include, for example, a diagnosing method for the risk of an ocular disease development or for the disease progression of an end-stage ocular disease by molecular profile analysis of the ocular anterior tissue microenvironment, comprising a step of measuring the concentration level of a metabolite appearing in the collected aqueous humor specimens by mass spectrometry (MS).Type: ApplicationFiled: June 7, 2021Publication date: July 13, 2023Applicants: SHIMADZU CORPORATION, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Morio UENO, Junji HAMURO, Kengo YOSHII, Chie SOTOZONO, Kazuhiro SONOMURA, Taka-Aki SATO
-
Publication number: 20230214998Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.Type: ApplicationFiled: July 29, 2022Publication date: July 6, 2023Applicants: Kyoto University, Kyoto Prefectural Public University CorporationInventors: Motomu Tanaka, Akihisa Yamamoto, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Hiroshi Tanaka, Munetoyo Toda, Chie Sotozono